The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Emerging therapeutic targets in endometrial cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Brocken, P., van der Heijden, H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus-Oei, L.-F. (2014) · Respiration · doi:10.1159/000347096 · Cited by 4,002
Pathology and Genetics of Tumours of the Breast and Female Genital Organs
Tavassoli, F. A., & Devilee, P. (2003) · International Agency for Research on Cancer eBooks · Cited by 2,800
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Two pathogenetic types of endometrial carcinoma
Bokhman, J. V. (1983) · Gynecologic Oncology · doi:10.1016/0090-8258(83)90111-7 · Cited by 2,494
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Höckel, M., Schlenger, K., Aral, B., Mitze, M., Schäffer, U., & Vaupel, P. W. (1996) · PubMed · Cited by 1,727
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., & Vergote, I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67063-8 · Cited by 1,497
The multifaceted mismatch-repair system
Jiricny, J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1907 · Cited by 1,370
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2806 · Cited by 1,226
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
Stallone, G., Schena, A., Infante, B., Di Paolo, S., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, L., Schena, F. P., & Grandaliano, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042831 · Cited by 990
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
CREASMAN, W., ODICINO, F., MAISONNEUVE, P., QUINN, M., BELLER, U., BENEDET, J., HEINTZ, A., NGAN, H., & PECORELLI, S. (2006) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(06)60031-3 · Cited by 966
Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 879
Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Role of the p16 tumor suppressor gene in cancer.
Liggett, W. H., & Sidransky, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1197 · Cited by 746
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8924 · Cited by 661
Hamilton, C. A., Cheung, M. K., Osann, K., Chen, L., Teng, N. N., Longacre, T. A., Powell, M. A., Hendrickson, M. R., Kapp, D. S., & Chan, J. K. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603012 · Cited by 644
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 638
Self-citationA dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
Creasman, W. T., Odicino, F., Maisonneuve, P., Beller, U., Benedet, J. L., Heintz, A. P. M., Ngan, H. Y. S., & Pecorelli, S. (2003) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(03)90116-0 · Cited by 579
Molecular and Pathologic Aspects of Endometrial Carcinogenesis
Hecht, J. L., & Mutter, G. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7173 · Cited by 535
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 466
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 420
mTOR signaling and drug development in cancer
Dancey, J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.21 · Cited by 417
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kalinsky, K., Jacks, L. M., Heguy, A., Patil, S., Drobnjak, M., Bhanot, U. K., Hedvat, C. V., Traina, T. A., Solit, D., Gerald, W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0632 · Cited by 401
(2002) · PubMed · Cited by 385
Bertagnolli, M. M., Niedzwiecki, D., Compton, C. C., Hahn, H. P., Hall, M., Damas, B., Jewell, S. D., Mayer, R. J., Goldberg, R. M., Saltz, L. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2071 · Cited by 364
Beta-catenin mutation in carcinoma of the uterine endometrium.
Fukuchi, T., Sakamoto, M., Tsuda, H., Maruyama, K., Nozawa, S., & Hirohashi, S. (1998) · PubMed · Cited by 361
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Pollock, P. M., Gartside, M. G., Dejeza, L. C., Powell, M. A., Mallon, M. A., Cancer Genome Project, Davies, H., Mohammadi, M., Futreal, P. A., Stratton, M. R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210529 · Cited by 307
Brachmann, S. M., Hofmann, I., Schnell, C., Fritsch, C., Wee, S., Lane, H., Wang, S., Garcia-Echeverria, C., & Maira, S.-M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905152106 · Cited by 303
Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas
McCluggage, W. G. (2002) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2002.01151.x · Cited by 302
Fleming, G. F., Sill, M. W., Darcy, K. M., McMeekin, D. S., Thigpen, J. T., Adler, L. M., Berek, J. S., Chapman, J. A., DiSilvestro, P. A., Horowitz, I. R., et al. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.025 · Cited by 300
Salvesen, H. B., Carter, S. L., Mannelqvist, M., Dutt, A., Getz, G., Stefansson, I. M., Raeder, M. B., Sos, M. L., Engelsen, I. B., Trovik, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806514106 · Cited by 290
Risinger, J. I., Hayes, K., Maxwell, G. L., Carney, M. E., Dodge, R. K., Barrett, J. C., & Berchuck, A. (1998) · PubMed · Cited by 285
Determinants of Rapamycin Sensitivity in Breast Cancer Cells
Noh, W.-C., Mondesire, W. H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G. B., Hung, M.-C., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0043 · Cited by 285
Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
Slomovitz, B. M., Lu, K. H., Johnston, T., Coleman, R. L., Munsell, M., Broaddus, R. R., Walker, C., Ramondetta, L. M., Burke, T. W., Gershenson, D. M., et al. (2010) · Cancer · doi:10.1002/cncr.25515 · Cited by 269
Morrison, C., Zanagnolo, V., Ramirez, N., Cohn, D. E., Kelbick, N., Copeland, L., Maxwell, L. G., & Fowler, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4827 · Cited by 258
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Dedes, K. J., Wetterskog, D., Mendes-Pereira, A. M., Natrajan, R., Lambros, M. B., Geyer, F. C., Vatcheva, R., Savage, K., Mackay, A., Lord, C. J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001538 · Cited by 255
Self-citationAbnormalities of the APC/β-catenin pathway in endometrial cancer
Moreno-Bueno, G., Hardisson, D., Sánchez, C., Sarrió, D., Cassia, R., García-Rostán, G., Prat, J., Guo, M., Herman, J. G., Matías-Guiu, X., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205924 · Cited by 237
Mismatch repair deficient colorectal cancer in the era of personalized treatment
Hewish, M., Lord, C. J., Martin, S. A., Cunningham, D., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.18 · Cited by 235
Self-citationGeyer, F. C., Weigelt, B., Natrajan, R., Lambros, M. B., de Biase, D., Vatcheva, R., Savage, K., Mackay, A., Ashworth, A., & Reis‐Filho, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2675 · Cited by 233
Self-citationMcEllin, B., Camacho, C. V., Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R. M., & Burma, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4295 · Cited by 231
Lax, S. F., Pizer, E. S., Ronnett, B. M., & Kurman, R. J. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)80002-6 · Cited by 227
EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma
Thaker, P. H., Deavers, M., Celestino, J., Thornton, A., Fletcher, M. S., Landen, C. N., Kinch, M. S., Kiener, P. A., & Sood, A. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0589 · Cited by 211
Gandhi, A. G., Murphy-Graham, E., Petrosino, A., Chrismer, S. S., & Weiss, C. H. (2007) · Evaluation Review · doi:10.1177/0193841x06287188 · Cited by 211
Risinger, J. I., Maxwell, G. L., Chandramouli, G. V. R., Jazaeri, A. A., Aprelikova, O. N., Patterson, T., Berchuck, A., & Barrett, J. C. (2003) · PubMed · Cited by 208
Cirisano, F. D., Robboy, S. J., Dodge, R. K., Bentley, R. C., Krigman, H. R., Synan, I. S., Soper, J. T., & Clarke-Pearson, D. L. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5505 · Cited by 199
Clinical and Biological Significance of Vascular Endothelial Growth Factor in Endometrial Cancer
Kamat, A. A., Merritt, W. M., Coffey, D., Lin, Y. G., Patel, P. R., Broaddus, R., Nugent, E., Han, L. Y., Landen, C. N., Spannuth, W. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1017 · Cited by 192
Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.
Arnett-Mansfield, R. L., DeFazio, A., Wain, G., Jaworski, R. C., Byth, K., Mote, P. A., & Clarke, C. L. (2001) · PubMed · Cited by 174
McMeekin, D. S., Filiaci, V. L., Thigpen, J. T., Gallion, H. H., Fleming, G. F., & Rodgers, W. H. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.04.032 · Cited by 172
The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas
Köbel, M., Reuss, A., Bois, A. D., Kommoss, S., Kommoss, F., Gao, D., Kalloger, S. E., Huntsman, D. G., & Gilks, C. B. (2010) · The Journal of Pathology · doi:10.1002/path.2744 · Cited by 170
Clinicopathologic Significance of Defective DNA Mismatch Repair in Endometrial Carcinoma
Black, D., Soslow, R. A., Levine, D. A., Tornos, C., Chen, S. C., Hummer, A. J., Bogomolniy, F., Olvera, N., Barakat, R. R., & Boyd, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1574 · Cited by 166
Salvesen, H. B., Iversen, O. E., & Akslen, L. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1382 · Cited by 166
Khalifa, M. A., Mannel, R. S., Haraway, S. D., Walker, J., & Min, K.-W. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1092 · Cited by 162
Jongen, V., Briët, J., de Jong, R., ten Hoor, K., Boezen, M., van der Zee, A., Nijman, H., & Hollema, H. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.10.032 · Cited by 162
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
Shoji, K., Oda, K., Nakagawa, S., Murayama-Hosokawa, S., Nagae, G., Uehara, Y., Sone, K., Miyamoto, Y., Hiraike, H., Hiraike-Wada, O., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605109 · Cited by 154
Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer
Lukes, A. S., Kohler, M. F., Pieper, C. F., Kerns, B. J., Bentley, R. C., Rodriguez, G. C., Soper, J. T., Clarke‐Pearson, D. L., Bast, R. C., & Berchuck, A. (1994) · Cancer · Cited by 154
Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148
Oza, A. M., Eisenhauer, E. A., Elit, L. M., Cutz, J.-C., Sakurada, A., Tsao, M., Hoskins, P. J., Biagi, J. J., Ghatage, P., Mazurka, J. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8808 · Cited by 152
Byron, S. A., Gartside, M. G., Wellens, C. L., Mallon, M. A., Keenan, J. B., Powell, M. A., Goodfellow, P. J., & Pollock, P. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0770 · Cited by 149
Moreno‐Bueno, G., Hardisson, D., Sarrió, D., Sánchez, C., Cassia, R., Prat, J., Herman, J. G., Esteller, M., Matías‐Guiu, X., & Palacios, J. (2003) · The Journal of Pathology · doi:10.1002/path.1310 · Cited by 138
Schlosshauer, P. W., Ellenson, L. H., & Soslow, R. A. (2002) · Modern Pathology · doi:10.1097/01.mp.0000028573.34289.04 · Cited by 129
Vascular Proliferation Is Important for Clinical Progress of Endometrial Cancer
Stefansson, I. M., Salvesen, H. B., & Akslen, L. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1163 · Cited by 128
Catasús, L., Gallardo, A., Cuatrecasas, M., & Prat, J. (2007) · Modern Pathology · doi:10.1038/modpathol.3800992 · Cited by 126
Villella, J., COHEN, S., Smith, D. H., Hibshoosh, H. H., & Hershman, D. L. (2006) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-00009577-200609000-00027 · Cited by 123
Pallarés, J., Bussaglia, E., Martínez‐Guitarte, J., Dolcet, X., Llobet‐Navàs, D., Rué, M., Sánchez‐Verde, L., Palacios, J., Prat, J., & Matías‐Guiu, X. (2004) · Modern Pathology · doi:10.1038/modpathol.3800347 · Cited by 122
Catasús, L., Gallardo, A., Cuatrecasas, M., & Prat, J. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.5 · Cited by 122
Salvesen, H. B., Das, S., & Akslen, L. A. (2000) · PubMed · Cited by 121
ElSahwi, K. S., Bellone, S., Cocco, E., Cargnelutti, M., Casagrande, F., Bellone, M., Abu-Khalaf, M., Buza, N., Tavassoli, F. A., Hui, P., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605448 · Cited by 119
Papillary Serous and Clear Cell Type Lead to Poor Prognosis of Endometrial Carcinoma in Black Women
Matthews, R., Hutchinson-Colas, J. A., Maiman, M. A., et al. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1997.4617 · Cited by 117
Santin, A. D., Zhan, F., Canè, S., Bellone, S., Palmieri, M., Thomas, M., Burnett, A., Roman, J. J., Cannon, M. J., Shaughnessy, J. D., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602480 · Cited by 115
Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence
Fujimoto, T., Nanjyo, H., Fukuda, J., Nakamura, A., Mizunuma, H., Yaegashi, N., Sugiyama, T., Kurachi, H., Sato, A., & Tanaka, T. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.10.019 · Cited by 114
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
Konecny, G. E., Venkatesan, N., Yang, G., Dering, J., Ginther, C., Finn, R. S., Rahmeh, M., Fejzo, M. S., Toft, D. O., Jiang, S.-W., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604278 · Cited by 112
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma
Livasy, C., Reading, F. C., Moore, D., Boggess, J. F., & Lininger, R. A. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.07.124 · Cited by 111
Jia, L., Liu, Y., Yi, X., Miron, A., Crum, C. P., Kong, B., & Zheng, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4837 · Cited by 110
A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer
Colombo, N., McMeekin, S., Schwartz, P. E., Kostka, J., Sessa, C., Gehrig, P. A., Holloway, R., Braly, P. S., Matei, D. E., & Einstein, M. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5516 · Cited by 100
Schwartz, D. L., Powis, G., Thitai-Kumar, A., He, Y., Bankson, J. A., Williams, R. R., Lemos, R., Oh, J., Volgin, A., Soghomonyan, S., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0981 · Cited by 100
Tsuda, H., YAMAMOTO, K., Inoue, T., Uchiyama, I., & Umesaki, N. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0980 · Cited by 90
EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma
Lee, J., Han, H. D., Shahzad, M. M. K., Kim, S. W., Mangala, L. S., Nick, A. M., Lü, C., Langley, R. R., Schmandt, R. E., Kim, H., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp231 · Cited by 90
McMeekin, D. S., Sill, M. W., Benbrook, D. M., Darcy, K. M., Stearns-Kurosawa, D. J., Eaton, L. A., & Yamada, S. D. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.019 · Cited by 89
ESR1 gene amplification in breast cancer: a common phenomenon?
Reis-Filho, J. S., Drury, S., Lambros, M. B. K., Marchiò, C., Johnson, N., Natrajan, R., Salter, J., Levey, P. M., Fletcher, O., Peto, J., et al. (2008) · Nature Genetics · doi:10.1038/ng0708-809b · Cited by 85
Self-citationInduction of human endometrial cancer cell senescence through modulation of HIF‐1α activity by EGLN1
Kato, H., Inoue, T., Asanoma, K., Nishimura, C., Matsuda, T., & Wake, N. (2005) · International Journal of Cancer · doi:10.1002/ijc.21488 · Cited by 84
The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer
Bilbao, C., Rodríguez, G., Ramírez‐Moreno, R., Falcón, O., León, L., Chirino, R., Rivero, J. F., Falcón, O., Díaz-Chico, B. N., Díaz-Chico, J. C., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21862 · Cited by 84
MacKay, H. J., Gallinger, S., Tsao, M., McLachlin, C. M., Tu, D., Keiser, K., Eisenhauer, E. A., & Oza, A. M. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.031 · Cited by 83
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma
Hayes, M. P., Douglas, W., & Ellenson, L. H. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.12.021 · Cited by 76
EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma
Lee, J., Stone, R. L., Lee, S. J., Nam, E. J., Roh, J., Nick, A. M., Han, H., Shahzad, M. M. K., Kim, H., Mangala, L. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0017 · Cited by 71
Kamat, A. A., Coffey, D., Merritt, W. M., et al. (2009) · Cancer · doi:10.1002/cncr.24335 · Cited by 67
Miyake, T. M., Yoshino, K., Enomoto, T., Takata, T., Ugaki, H., Kim, A., Fujiwara, K., Miyatake, T., Fujita, M., & Kimura, T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.11.004 · Cited by 65
Suehiro, Y., Okada, T., Okada, T., Anno, K., Okayama, N., Ueno, K., Hiura, M., Nakamura, M., Kondo, T., Oga, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4609 · Cited by 65
HER2が増幅されPI3K3CAが変異した乳癌細胞におけるPI3K/mTor二重阻害剤NVP‐BEZ235による特異的アポトーシス誘発
Saskia, M. B., Irmgard, H., Christian, S., et al. (2009) · Cited by 60
Increased expression of hypoxia-inducible factor 1α in type I and type II endometrial carcinomas
Pansare, V. M., Munkarah, A. R., Schimp, V. L., Arabi, H., Saed, G. M., Morris, R. T., & Ali‐Fehmi, R. (2006) · Modern Pathology · doi:10.1038/modpathol.3800718 · Cited by 58
Oza, A. M., Elit, L., Provencher, D. M., Biagi, J. J., Panasci, L., Sederias, J., Dancey, J. E., Tsao, M., & Eisenhauer, E. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5516 · Cited by 53
Angiogenic co‐operation of VEGF and stromal cell TP in endometrial carcinomas
Sivridis, E., Giatromanolaki, A. N., Anastasiadis, P. G., Georgiou, L., Gatter, K. C., Harris, A. L., Bicknell, R., & Koukourakis, M. I. (2002) · The Journal of Pathology · doi:10.1002/path.1060 · Cited by 49
p16andp15Alterations in Primary Gynecologic Malignancy
Wong, Y. F., Chung, T. K. H., Cheung, T. H., Nobori, T., Yim, S. F., Lai, K. W. H., Yu, A. L.-T., Diccianni, M. B., Li, T. Z., & Chang, A. M. Z. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1997.4669 · Cited by 45
P16 alterations increase the metastatic potential of endometrial carcinoma
Ignatov, A., Bischoff, J., Schwarzenau, C., Krebs, T., Kuester, D., Herrmann, K., Costa, S. D., Roessner, A., Semczuk, A., & Schneider‐Stock, R. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.07.037 · Cited by 43
Lebeau, A., Grob, T. J., Holst, F., Seyedi‐Fazlollahi, N., Moch, H., Terracciano, L., Turzynski, A., Choschzick, M., Sauter, G., & Simon, R. (2008) · The Journal of Pathology · doi:10.1002/path.2405 · Cited by 38
IMMUNOSUPPRESSIVE PROPERTIES OF FK-506 AND RAPAMYCIN
Thomson, A. W., & Woo, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90616-8 · Cited by 33
Miturski, R., Bogusiewicz, M., Ciotta, C., Bignami, M., Gogacz, M., & Burnouf, D. (2002) · Experimental Biology and Medicine · doi:10.1177/153537020222700805 · Cited by 20
(2000) · Pure Amsterdam UMC · doi:10.1002/1097-0142(20001015)89:8
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Cited by
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00130-0 · Cited by 1,514
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv484 · Cited by 1,386
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000609 · Cited by 767
Classification of endometrial carcinoma: more than two types
Murali, R., Soslow, R. A., & Weigelt, B. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70591-6 · Cited by 647
Stelloo, E., Bosse, T., Nout, R. A., MacKay, H. J., Church, D. N., Nijman, H. W., Leary, A., Edmondson, R. J., Powell, M. E., Crosbie, E. J., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.43 · Cited by 486
Metadata
- Authors
- Dedes, K. J., Wetterskog, D., Ashworth, A., Kaye, S. B., & Reis-Filho, J. S.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2011-01-11
- Volume
- 8
- Issue
- 5
- Pages
- 261-271
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2045448921
- Cited by
- 270
- References
- 114
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.